Dutton

Dutton Therapeutics is a pre-clinical stage biotechnology company dedicated to developing transformative gene therapies for patients with X-linked adrenoleukodystrophy (X-ALD). Launched by Atlas Venture, the company focuses on addressing the underlying genetic cause of X-ALD, a rare and devastating neurodegenerative disorder caused by mutations in the ABCD1 gene. Dutton's approach utilizes advanced viral vector technology to deliver functional copies of the ABCD1 gene to the central nervous system, aiming to halt disease progression. The company's lead programs are designed to provide a durable, one-time treatment option for the cerebral form of the disease, which currently has limited therapeutic interventions.